Drug intelligence / Profile preview

d-phenylalanyl-n-(3-methylbenzyl)-l-prolinamide

Development stage: Unknown
Modality: Small Molecules

Overview

D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide is a small molecule dipeptide derivative. It is classified as an experimental compound and has been investigated for its potential as a prothrombin inhibitor. There are no approved indications or clinical trials reported for this drug[1][5][8]. The compound belongs to the class of organic compounds known as dipeptides and features two aromatic rings in its structure[4][5]. Its mechanism of action involves inhibition of prothrombin, but detailed pharmacological data and clinical development status are limited[1].

Other names: D-Phenylalanyl-N-(3-Methylbenzyl)-L-ProlinamideDB07133DB-07133DB 0713351U

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on d-phenylalanyl-n-(3-methylbenzyl)-l-prolinamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on d-phenylalanyl-n-(3-methylbenzyl)-l-prolinamide.

Explore the full profile